exit_to_appLogin
FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors
Signup
Frontpage iOS AppFrontpage Android App
forum

GLAXO Share Price Discussion

GlaxoSmithKline Pharmaceuticals Ltd.
NSE: GLAXO | BSE: 500660 | ISIN: INE159A01016 | Sector: Pharmaceuticals and health care

GLAXO Rating

  • ★
    ★
  • ★
    ★
  • ★
    ★
  • ★
    ★
  • ★
    ★
3/5 (1 Ratings)
GLAXO Share Price *
1,341.35 -3.55 (-0.26%)
* (quote may be delayed)
Find answers to all your questions on live GLAXO message board: Is GLAXO buy or sell? Should I buy GLAXO shares? Why are GLAXO shares falling? Should I invest in GLAXO stock?

You can also check GLAXO share price target recommended by brokerages.

GLAXO Discussion Forum

NewsBot
 • GLAXO
•Feb 11 12:28 AM
@newsbot • Reputation: 2,308
Ranitidine recall forces GSK to alter Indian market strategy
GSK had initiated global voluntary recall of Ranitidine in September 2019, following reports of a probable cancer causing impurity called N‐nitrosodimethylamine (NDMA).
Moneycontrol
Like
reply
Reply
Sridhar Balakrishnan
 • GLAXO
•Feb 6 11:17 PM
@sridharbalakrishnan • Reputation: 11,482
GSK announces sale of Vemagal plant; takes Rs 640 crore hit on account of Zinetac recall - Times of India
Times of India brings the Latest & Top Breaking News on Politics and Current Affairs in India & around the World, Cricket, Sports, Business, Bollywood News and Entertainment, Science, Technology, Health & Fitness news & opinions from leading columnists.
The Times of India
Bad News for Pharmaceutical sector GlaxoSmithKline (GSK) Pharma - Bangalore
Yesterday night gave a very big Dinner in 5 star hotel to all Bangalore Employee & at the end of Dinner
GSK handed Termination Letter. With 6 months Salary Cheque.
GSK Pharma - Bangalore plant is clos...
Read more...
Like
reply
Reply
JJ Technicals
 • GLAXO
•Feb 6 4:33 PM
@jjtechnicals • Reputation: 2,044
GLAXO
Type
Sell
Instrument
GLAXO
Entry Price
₹1,362
Price@Trade
₹1,372.9
Target Price
₹1,330
Stop Price
₹1,388  ₹1,353
Valid Till
Feb 7, 2020 3:20 PM
Margin
₹1,362 approx for 1 Qty
Status
Exited
Exit Price
₹1,335.95
Net P&L
1.91% Profit
Like
reply
Reply (3)
Latest replies
TrackerBot @trackerbot
•
Feb 6 4:53 PM
Update
Trade Entered
Entry Price
₹1,362
JJ Technicals @jjtechnicals
•
Feb 6 5:51 PM
Update
Stoploss Trailed
Price @ Update
₹1,342
Original SL
₹1,388
New SL
₹1,353
JJ Technicals @jjtechnicals
•
Feb 6 5:55 PM
Update
Exited
Exit Price
₹1,335.95
Net P&L
1.91% Profit
NewsBot
 • GLAXO
•Feb 5 11:13 PM
@newsbot • Reputation: 2,308
XLRI completes final placement in two days, average salary up by Rs 2 lakh at Rs 24.3 lakh pa
The final recruitment process saw participation from 108 recruiters with 362 domestic and international offers.
Moneycontrol
Like
reply
Reply
NewsBot
 • GLAXO
•Feb 4 5:13 PM
@newsbot • Reputation: 2,308
GSK Pharma share price tanks 10% to hit 3-month low after Q3 loss of Rs 661 crore
The results were impacted due to voluntary global recall of ranitidine products, including Zinetac, said GlaxoSmithKline Pharmaceuticals Managing Director A Vaidheesh.
Moneycontrol
Like
reply
Reply
Alpha Signals
 • GLAXO
•Feb 4 4:38 PM
@ravikanthchopperla • Reputation: 11,825
GlaxoSmithKline Pharma plunges 13% on net loss of Rs 661 crore in Q3 - Business Standard
04-Feb-2020 09:53:09 AM
Shares of GlaxoSmithKline Pharmaceuticals tanked 13 per cent to Rs 1,429 on the BSE on Tuesday after the company reported a consolidated net loss of Rs 661 crore for ...
Read more...
Like
reply
Reply
NewsBot
 • GLAXO
•Feb 4 2:18 AM
@newsbot • Reputation: 2,308
GlaxoSmithKline Pharma posts net loss of Rs 661.16cr for December quarter
The company had posted a net profit of Rs 113.67 crore for the corresponding period of the previous financial year, GlaxoSmithKline Pharmaceuticals said in a filing to the BSE.
Moneycontrol
Like
reply
Reply
TTA
 • GLAXO
•Dec 24 8:55 PM
@TTA • Reputation: 20,422
GSK PHARMA: LIC SELLS 34 LAKH SHARES (2% EQUITY) OF CO VIA OPEN MARKET ON DECEMBER 19
Like
reply
Reply
M
MANOJ GOYAL
 • GLAXO
•Dec 7 9:12 PM
@manojgoyal • Reputation: 0
Hi
Like
reply
Reply
Alpha Signals
 • GLAXO
•Nov 20 7:31 PM
@ravikanthchopperla • Reputation: 11,825
GLAXO - 446953

1
reply
Reply
M PRICE PLOTTING
 • GLAXO
•Nov 15 2:50 PM
@mpriceplotting • Reputation: 1,067
For the Job and Part time Traders 😘
This is one more simple example of Simplicity with out Charts ..
Glaxo bullish 1350 and see high 1703 in just 15 days so be in trend always
Like
reply
Reply
TradeAdda
 • GLAXO
•Oct 22 10:48 PM
@nishantshah91 • Reputation: 3,415
Glaxo Pharma – Q2 FY20 (Unaudited – Cons.)
Share price – 1435
Total revenue from operations at 882.02 Cr
816.31 Cr (8.03%) YoY | 787.91 Cr (11.92%) QoQ
Six month ended revenue: 1669.9 Cr Vs. 1551.9 Cr (7.02%)
Net Profit of 502.7 Cr
100.8 Cr (402.43%) YoY 113.5 (345.07%) QoQ
Six...
Read more...
1
reply
Reply
NewsBot
 • GLAXO
•Oct 22 10:43 PM
@newsbot • Reputation: 2,308
GSK Pharma Q2 profit at Rs 503 cr
Revenue from operations stood at Rs 882.02 crore for the quarter under review as against Rs 816.31 crore in the same period a year ago.
Moneycontrol
Like
reply
Reply
NewsBot
 • GLAXO
•Oct 10 1:38 AM
@newsbot • Reputation: 2,308
Indian pharma market sees growth of 11.5% in Q2FY20
The July-October period saw outbreaks of infectious diseases in many parts of the country, aiding the growth of anti-infective segment to 14 percent YoY in the second quarter, beating overall IPM growth.
Moneycontrol
Like
reply
Reply
NewsBot
 • GLAXO
•Oct 9 11:08 PM
@newsbot • Reputation: 2,308
Indian pharma market registers growth of 11.5% in Q2FY20
The July-October period saw outbreaks of infectious diseases in many parts of the country, aiding the growth of anti-infective segment to 14 percent YoY in the second quarter, beating overall IPM growth.
Moneycontrol
Like
reply
Reply
NewsBot
 • GLAXO
•Sep 30 7:53 PM
@newsbot • Reputation: 2,308
Ranitidine controversy: Which Indian pharma companies stand to lose?
Moneycontrol
Like
reply
Reply
NewsBot
 • GLAXO
•Sep 26 4:03 PM
@newsbot • Reputation: 2,308
GSK Pharma slips 5% after halting sale of acidity medicine Zinetac, other ranitidine products
The company has made the decision to initiate a voluntary recall of Zinetac Tablets 150 mg and 300 mg products manufactured in India.
Moneycontrol
Like
reply
Reply
NewsBot
 • GLAXO
•Sep 26 1:58 PM
@newsbot • Reputation: 2,308
Stocks in the news: DHFL, Cipla, GSK Pharma, Sterlite Tech, Future Enterprises, CG Power, SRF
DHFL | Cipla | GlaxoSmithKline Pharma | Adani Enterprises | Future Enterprises and Sterlite Technologies are among stocks which are in news today.
Moneycontrol
Like
reply
Reply
NewsBot
 • GLAXO
•Sep 26 1:43 PM
@newsbot • Reputation: 2,308
Stocks in the news: DHFL, Cipla, GSK Pharma, Adani Enterprises, Future Enterprises, CG Power, SRF
DHFL | Cipla | GlaxoSmithKline Pharma | Adani Enterprises | Future Enterprises and Sterlite Technologies are among stocks which are in news today.
Moneycontrol
Like
reply
Reply
NewsBot
 • GLAXO
•Sep 26 1:18 PM
@newsbot • Reputation: 2,308
Stocks in the news: DHFL, Cipla, GSK Pharma, Adani Enterprises, Future Enterprises, Sterlite Tech
DHFL | Cipla | GlaxoSmithKline Pharma | Adani Enterprises | Future Enterprises and Sterlite Technologies are among stocks which are in news today.
Moneycontrol
Like
reply
Reply
NewsBot
 • GLAXO
•Sep 26 2:18 AM
@newsbot • Reputation: 2,308
Trade Setup for Thursday: Top 15 things to know before Opening Bell
According to the pivot charts, key support level for Nifty is placed at 11,382.53, followed by 11,324.87. If the index starts moving up, key resistance levels to watch out for are 11,531.43 and 11,622.67.
Moneycontrol
Like
reply
Reply
NewsBot
 • GLAXO
•Sep 26 12:28 AM
@newsbot • Reputation: 2,308
GSK suspends Ranitidine distribution in India, regulators seek drug testing data from pharma cos
Sources within pharma industry told Moneycontrol that Dr Reddy’s and Saraca Laboratories are two big suppliers of the Ranitidine active pharmaceutical ingredient (API) globally, from which most other companies source the API to formulate the drug.
Moneycontrol
Like
reply
Reply
Great Eagle Analysis
 • GLAXO
•Sep 19 4:34 AM
@guptan • Reputation: 3,156
GLAXO - chart - 365719
Glaxo
Like
reply
Reply
Tipu Pahan
 • GLAXO
•Sep 11 4:25 AM
@tipupahan • Reputation: -2,195
CASH INTRADAY CALL (11 SEPT 2019)
GLAXO BUY ABOVE 1333M SL - 1321, TGT - 1364 & 1402
Like
reply
Reply (1)
Latest replies
Tipu Pahan @tipupahan
•
Sep 12 3:47 AM
FROM 1333 TO 1400 (67 POINTS) PROFIT (+5% UP)
NewsBot
 • GLAXO
•Sep 9 11:33 PM
@newsbot • Reputation: 2,308
Pharma companies cheer good monsoon as demand for anti-infective drugs rises
Anti-infective drugs grew at 15.3 percent YoY in August, compared to Indian pharmaceutical market growth of 9.4 percent.
Moneycontrol
Like
reply
Reply
NewsBot
 • GLAXO
•Sep 4 12:13 AM
@newsbot • Reputation: 2,308
Government scrambles to address shortage of rabies vaccine after GSK exit
Sources within the vaccine industry said that one of the main reasons for the current shortage was due to the exit of Chiron Behring Vaccines, a unit of GlaxoSmithKline (GSK).
Moneycontrol
Like
reply
Reply
NewsBot
 • GLAXO
•Aug 21 3:29 PM
@newsbot • Reputation: 2,308
Focus on selective products, therapies starting to pay dividends: GSK Pharma
Vaidheesh hinted at new launches such as a vaccine (Bexsero) to protect infants against Meningitis B and a new drug to treat autoimmune disorders
Moneycontrol
Like
reply
Reply
NewsBot
 • GLAXO
•Aug 7 9:38 PM
@newsbot • Reputation: 2,308
Hold GlaxoSmithKline Consumer Healthcare; target of Rs 7972: Prabhudas Lilladher
Prabhudas Lilladher recommended hold rating on GlaxoSmithKline Consumer Healthcare with a target price of Rs 7972 in its research report dated August 05, 2019.
moneycontrol.com
Like
reply
Reply
NewsBot
 • GLAXO
•Jul 22 10:38 PM
@newsbot • Reputation: 2,308
Like
reply
Reply
NewsBot
 • GLAXO
•Jul 16 2:38 AM
@newsbot • Reputation: 2,308
Like
reply
Reply
Great Eagle Analysis
 • GLAXO
•Jul 13 6:11 PM
@guptan • Reputation: 3,156
GLAXO - chart - 266756
Galxo
Like
reply
Reply
NewsBot
 • GLAXO
•Jul 10 7:53 PM
@newsbot • Reputation: 2,308
Like
reply
Reply
NewsBot
 • GLAXO
•Jul 9 10:18 PM
@newsbot • Reputation: 2,308
Like
reply
Reply
NewsBot
 • GLAXO
•Jun 15 3:18 AM
@newsbot • Reputation: 2,308
Like
reply
Reply
NewsBot
 • GLAXO
•May 24 7:13 PM
@newsbot • Reputation: 2,308
Like
reply
Reply
S
Shubham
 • GLAXO
•Mar 13 5:04 PM
@shubham-rkY76MIDE • Reputation: 0
It will grow huge in next 2 days
Like
reply
Reply
NewsBot
 • GLAXO
•Jan 17 10:22 PM
@newsbot • Reputation: 2,308
Like
reply
Reply
NewsBot
 • GLAXO
•Jan 16 3:37 PM
@newsbot • Reputation: 2,308
Like
reply
Reply
NewsBot
 • GLAXO
•Dec 10 9:12 PM
@newsbot • Reputation: 2,308
Like
reply
Reply
NewsBot
 • GLAXO
•Dec 5 2:57 AM
@newsbot • Reputation: 2,308
Like
reply
Reply

  • GLAXO - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization22,020.76
    Enterprise Value20,865.43
    Price to Earnings50.18
    Price to Book Value10.28
    Return on Capital Employed0.26
    Return on Equity0.17
    Face Value10
    Dividend Yield0.02

  • GLAXO Share Price - Technicals

    keyboard_arrow_down
    GLAXO - 52 Week High₹1,748
    GLAXO - 52 Week Low₹1,130

  • GLAXO - Brokerage Reports

    keyboard_arrow_down
    DateBrokerageCallTarget
    21-May-19Motilal OswalNeutral1,350
    23-Oct-18CentrumSell950
    26-Jul-18CentrumSell950
    25-May-18Motilal OswalNeutral1,250
    3-Feb-18Motilal OswalNeutral1,250
    GLAXO Brokerage Price Target

  • GLAXO Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    Feb 1913451362.0513251341.35
    Feb 181321.1135013191344.9
    Feb 171334.91334.913051317.05
    Feb 141353.81358.813271335.95
    Feb 1313131349.9513001343.9

  • GLAXO Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹1,472.23
    30 Day Moving Average₹1,524.19
    50 Day Moving Average₹1,568.03
    100 Day Moving Average₹1,560.18
    200 Day Moving Average₹1,404.79

  • GLAXO - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue2,895.882,994.51-0.03
    Operating Profit508.44417.50.22
    Profit Before Tax541.58511.080.06
    Net Income351.99336.780.05

  • GLAXO - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-19Mar-18 % Change
    Shareholder's Funds2,1422,079.950.03
    Total Liabilities1,7671,901.27-0.07
    Total Assets3,9093,981.22-0.02

  • GLAXO - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity474.77233.131.04
    Cash from Investing Activity-107.01303.24-1.35
    Cash from Financing Activity-306.63-510.76-0.4
    Net Cash Flow61.1225.611.39

  • GLAXO - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets0.090.11
    Return on Equity0.170.17
    Return on Capital Employed0.260.25

  • GLAXO - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue-0.12
    3 Year CAGR Growth in Operating Profit-0.12
    3 Year CAGR Growth in EBIDTA-0.25
    3 Year CAGR Growth in Net Income-0.25
    3 Yr CAGR Growth - Diluted EPS-0.25

  • GLAXO - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue0.1
    5 Year CAGR Growth in Operating Profit-0.24
    5 Year CAGR Growth in EBIDTA-0.33
    5 Year CAGR Growth in Net Income-0.39
    3 Yr CAGR Growth - Diluted EPS-0.39

  • GLAXO - Recent News

    keyboard_arrow_down
    NewsBot
    Feb 11 12:28 AM
    Ranitidine recall forces GSK to alter Indian market strategy
    Moneycontrol
    NewsBot
    Feb 5 11:13 PM
    XLRI completes final placement in two days, average salary up by Rs 2 lakh at Rs 24.3 lakh pa
    Moneycontrol
    NewsBot
    Feb 4 5:13 PM
    GSK Pharma share price tanks 10% to hit 3-month low after Q3 loss of Rs 661 crore
    Moneycontrol
    NewsBot
    Feb 4 2:18 AM
    GlaxoSmithKline Pharma posts net loss of Rs 661.16cr for December quarter
    Moneycontrol
    NewsBot
    Oct 22 10:43 PM
    GSK Pharma Q2 profit at Rs 503 cr
    Moneycontrol
    NewsBot
    Oct 10 1:38 AM
    Indian pharma market sees growth of 11.5% in Q2FY20
    Moneycontrol
    NewsBot
    Oct 9 11:08 PM
    Indian pharma market registers growth of 11.5% in Q2FY20
    Moneycontrol
    NewsBot
    Sep 30 7:53 PM
    Ranitidine controversy: Which Indian pharma companies stand to lose?
    Moneycontrol
    NewsBot
    Sep 26 4:03 PM
    GSK Pharma slips 5% after halting sale of acidity medicine Zinetac, other ranitidine products
    Moneycontrol
    NewsBot
    Sep 26 1:58 PM
    Stocks in the news: DHFL, Cipla, GSK Pharma, Sterlite Tech, Future Enterprises, CG Power, SRF
    Moneycontrol

  • GLAXO - Related Communities

    keyboard_arrow_down
    Sun Pharmaceutical Industries Ltd. S...
    Aurobindo Pharma Ltd. Sector: Pharma...
    Biocon Ltd. Sector: Pharmaceuticals ...
    Cipla Ltd. Sector: Pharmaceuticals a...
    Dr. Reddy's Laboratories Ltd. Sector...
    Lupin Ltd. Sector: Pharmaceuticals an...
    Piramal Enterprises Ltd. Sector: Phar...
    Divi's Laboratories Ltd. Sector: Pha...
    Glenmark Pharmaceuticals Ltd. Sector...
    Strides Pharma Science Ltd. Sector: P...
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.
FrontPage Apps
Frontpage iOS AppFrontpage Android App
HelpAboutPrivacyTermsDisclaimersRefunds